Representing defendant Sandoz Inc. in a proceeding under the Affordable Care Act’s Biologics Price Competition and Innovation Act (BPCIA) to bring a biosimilar to an antibody product to market for osteoporosis and oncology indications.
Represented plaintiff Seagen (f/k/a Seattle Genetics) in an infringement action involving patents infringed by Daiichi’s Enhertu treatment. The jury rendered its verdict of willful infringement and no invalidity after less than two hours of deliberation, awarding the entire $41.8 million Seagen requested.
Represented plaintiff in a trade secret and breach of contract dispute with a former employee and a co-founder involving gene therapy for neurodenegerative diseases. Successfully obtained favorable outcome.